SABCS 2025 – pumitamig replicates breast cancer findings
Global phase 2 data in TNBC look similar to earlier results in China.
NACLC 2025 – BioNTech gets a gotistobart boost
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
BioNTech’s big gotistobart day approaches
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
Pfizer speeds ahead with bispecific development
The company will imminently start its third pivotal trial of PF-08634404.
Gastrointestinal is next for pumitamig
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
In triple-negative pumitamig concedes PD-L1-high disease
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
